# Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function

> **NCT03718533** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 10 (actual)

## Conditions studied

- Poor Graft Function

## Interventions

- **DRUG:** Eltrombopag

## Key facts

- **NCT ID:** NCT03718533
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-17
- **Primary completion:** 2020-11-03
- **Final completion:** 2020-11-03
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** In the context of COVID-19 pandemic, the benefit / risk ratio of the participation of a patient with pancytopenia could be compromised. The decision of this premature termination was not the consequence of any safety reason inherent to the drug.
- **Last updated:** 2024-02-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03718533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03718533, "Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03718533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*